Lung Cancer | Specialty

Emerging Landscape of Immunotherapy in NSCLC

August 27th 2015

Bevacizumab in EGFR-Mutant NSCLC

August 27th 2015

Bevacizumab in Nonsquamous NSCLC

August 27th 2015

Bevacizumab in Malignant Pleural Mesothelioma

August 27th 2015

New Therapies for Squamous NSCLC

August 27th 2015

Cabozantinib in RET-Rearranged NSCLC

August 27th 2015

Dual Targeting of BRAF and MEK in NSCLC

August 27th 2015

CNS Activity With Next-Generation ALK Inhibitors

August 27th 2015

Overcoming EGFR Inhibitor Resistance in Non-T790M-Positive NSCLC

August 27th 2015

Impressive Findings for Next-Generation EGFR Inhibitors

August 27th 2015

Upfront EGFR-Targeted Therapy for NSCLC

August 27th 2015

FDA Accepts Afatinib Application for Squamous Cell Lung Cancer

August 26th 2015

The FDA has accepted an application for afatinib (Gilotrif) as a treatment for patients with squamous cell non–small cell lung cancer following progression on chemotherapy.

Stephenson Cancer Center Aims for NCI Designation

August 21st 2015

Brentuximab Vedotin Label Expanded, Top-Line Results for CLL, NSCLC, and More

August 21st 2015

Atezolizumab Again Achieves Phase II Success in PD-L1-Positive Lung Cancer

August 17th 2015

Atezolizumab met the primary endpoint of objective response in PD-L1–positive patients with advanced non–small cell lung cancer in the phase II BIRCH trial.

Dr. Krug on Intra-Pleural Administration of GL-ONC1 in Patients With Malignant Pleural Effusion

August 17th 2015

Lee M. Krug, MD, associate attending physician, Division of Thoracic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, discusses a phase I study examining intra-pleural administration of GL-ONC1 in patients with malignant pleural effusion.

Effort to "Harmonize" PD-L1 Assays Launched in NSCLC

August 14th 2015

Amid continuing excitement over the potential for immunotherapies targeting the PD-1/PD-L1 pathway, two major questions have loomed over PD-L1 expression levels as a biomarker for this emerging new class of drugs.

Dr. Walter Curran on Developments in Radiation Delivery for Patients with Lung Cancer

August 10th 2015

Walter J. Curran, Jr., MD, Executive Director, Winship Cancer Institute of Emory University, Associate Vice President, Woodruff Health Sciences Center, discusses new developments in the delivery of radiation for patients with lung cancer.

Biomarker Chase Continues With Checkpoint Agents in Lung Cancer

August 10th 2015

Achieving true precision medicine with PD-1/PD-L1 agents in NSCLC will only come from biomarker-driven frontline regimens delivered to the right patients.

Lenvatinib Breakthrough Designation, New Drug Applications for NSCLC, STS, and More

August 7th 2015